Fuling Technology
001356
KLT
831689
Hand Enterprise Solutions
300170
4
GRANDTECH
835184
5
Doushen(Beijing) Education & Technology Inc.
300010
US Stock MarketDetailed Quotes
SWTX SpringWorks Therapeutics
- 35.930
- +0.930+2.66%
Trading Jan 23 15:24 ET
2.67BMarket Cap-9.24P/E (TTM)
35.960High34.420Low774.94KVolume34.750Open35.000Pre Close27.42MTurnover1.12%Turnover RatioLossP/E (Static)74.39MShares53.92052wk High5.02P/B2.48BFloat Cap28.21052wk Low--Dividend TTM69.04MShs Float96.480Historical High--Div YieldTTM4.40%Amplitude13.600Historical Low35.381Avg Price1Lot Size
SpringWorks Therapeutics News
TD Cowen Maintains SpringWorks Therapeutics(SWTX.US) With Buy Rating, Maintains Target Price $63
TD Cowen Remains a Buy on Springworks Therapeutics (SWTX)
Barclays Maintains SpringWorks Therapeutics(SWTX.US) With Buy Rating, Maintains Target Price $63
BofA Securities Maintains SpringWorks Therapeutics(SWTX.US) With Buy Rating, Maintains Target Price $55
SWTX Announces 2024 Preliminary Results, 2025 Goals, Stock Down
A Quick Look at Today's Ratings for SpringWorks Therapeutics(SWTX.US), With a Forecast Between $55 to $63
Buy Rating Affirmed for Springworks Therapeutics: Strong Product Potential and Strategic Growth Outlook
Springworks Therapeutics Down Over 13%, on Pace for Largest Percent Decrease Since August 2022 -- Data Talk
SpringWorks Therapeutics To Present At J.P. Morgan Healthcare Conference; Webcast At 2:15 PM ET
Update: Springworks Therapeutics Reports Preliminary Q4, Full-Year 2024 Net Product Revenue
TD Sees 'Some Disappointment' With Lack of SpringWorks Therapeutics M&A News
SpringWorks Therapeutics Shares Are Trading Lower Following Q4 and FY24 Financial Results
SpringWorks Therapeutics | 8-K: SpringWorks Therapeutics Reports Preliminary Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates at 43rd Annual J.P. Morgan Healthcare Conference
SpringWorks Therapeutics Reported Q4 OGSIVEO Revenue Of $61.5M, Cash Balance Of $461.9M
Express News | Rappta Therapeutics : Financials Include a $13 Mln Upfront Payment and Potential Milestones Payments
Express News | SpringWorks Therapeutics Inc - to Seek EU Approval for Ogsiveo, Launch in Germany Mid-2025
Express News | SpringWorks Therapeutics : Preliminary Q4 and 2024 U.S. Net Product Revenue for Ogsiveo Were $61.5 Mln and $172.0 Mln
Express News | Rappta Therapeutics Enters Into a Global License Agreement With SpringWorks Therapeutics for a Pre-Clinical First-in-Class Molecular Glue Targeting Pp2a
Express News | SpringWorks Therapeutics: Expects Cash Position to Fund Operations Through Profitability, Which Co Anticipates Achieving in First Half 2026
Plug Power, Capri And Frontline Are Among Top Mid Cap Gainers Last Week (Jan 6-10): Are The Others In Your Portfolio?
Trending Stocks
Investment Course
Top 5 Industries for Stock Trading under Trump's Second Term
Stocks & Industries to Watch Under Trump's Second Presidency
With mooomoo, find out which stocks and industries may benefit from Trump's second presidency, based on his first administration's track record.
Stocks & Industries to Watch Under Trump's Second Presidency
Key takeaways Tech stocks underwent substantial growth due to tax cuts and reduced corporate regulations in Trump's first term along with defense and aerospace
Discussing
December CPI comes in as expected, is that enough?
U.S. December CPI rose 2.9% year-on-year, aligning with expectations but marking a three-month inflation increase trend. The market reacted
In One Chart
Jan 15 22:05
Here's the Breakdown for December CPI, in One Chart